BEAM Beam Therapeutics Inc.
Healthcare$29.79+4.02%ClosedMarket Cap: $3.06B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.54
P/S
17.96
EV/EBITDA
-46.33
DCF Value
$-35.65
FCF Yield
-13.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-32.4%
Operating Margin
-226.6%
Net Margin
-39.7%
ROE
-5.9%
ROA
-4.4%
ROIC
-26.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $31.7M | 100.0% | $-107.2M | $-94.3M | $— | — |
| Q4 null | $114.1M | 95.0% | $-17.4M | $244.3M | $— | — |
| FY null | $139.7M | 84.0% | $-383.7M | $-80.0M | $— | — |
| Q3 null | $9.7M | -1031.9% | $-126.8M | $-112.7M | $— | — |
| Q2 null | $8.5M | -1102.0% | $-120.2M | $-102.3M | $— | — |
| Q1 null | $7.5M | -1222.8% | $-119.3M | $-109.3M | $— | — |
| Q4 null | $30.1M | -237.4% | $-100.0M | $-90.4M | $— | — |
| FY null | $63.5M | -478.7% | $-415.6M | $-376.7M | $— | — |
| Q3 null | $14.3M | -560.6% | $-106.5M | $-96.7M | $— | — |
| Q2 null | $11.8M | 100.0% | $-104.9M | $-91.1M | $— | — |
| Q1 null | $7.4M | -1044.6% | $-104.1M | $-98.7M | $— | — |
| Q4 2023 | $316.2M | 55.7% | $132.9M | $142.8M | $1.73 | — |